GSK has invested $7.7 million in a new pilot vaccine facility with the hope Australian manufacturing innovation could reduce cost of vaccination in developing world.
Access to healthcare
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
GSK's Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices.
How we do business
The inaugural PharmAus showcase saw GSK and 19 other innovative pharmaceutical companies illustrate our industry’s investment and collaboration with Australia’s top research institutes, universities, biotechs and patients, to deliver the latest breakthroughs in treatment.
Isaac Barr joined GSK as a chemical engineer graduate in 2015. Here he talks about his first year at our Boronia manufacturing plant supporting the team to build a new pilot vaccine facility.
Philip Leslie leads innovation at GSK's manufacturing site in Boronia. He was recognised at the 2017 Victorian Manufacturing Awards as a Hall of Fame honoree.